In the pilot study, recombinant CXCL12 treatment for cats with early CKD was safe and feasible in a general practice setting, and we measured changes in kidney disease stage progression, USG, serum creatinine, and SDMA in both groups. Here, CXCL12 is linked to chronic kidney disease.